Cargando…
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537095/ https://www.ncbi.nlm.nih.gov/pubmed/37765080 http://dx.doi.org/10.3390/ph16091272 |
_version_ | 1785113022481563648 |
---|---|
author | Imbrizi, Marcello Magro, Fernando Coy, Claudio Saddy Rodrigues |
author_facet | Imbrizi, Marcello Magro, Fernando Coy, Claudio Saddy Rodrigues |
author_sort | Imbrizi, Marcello |
collection | PubMed |
description | Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule for the treatment of IBD, we still do not have drugs that promote disease remission in a generalized way. We carried out a narrative review on therapeutic advances in the treatment of IBD, the mechanisms of action, and the challenges facing the therapeutic goals in the treatment of IBD. Salicylates are still used in the treatment of Ulcerative Colitis. Corticosteroids have an indication restricted to the period of therapeutic induction due to frequent adverse events, while technologies with less systemic action have been developed. Most immunomodulators showed a late onset of action, requiring a differentiated initial strategy to control the disease. New therapeutic perspectives emerged with biological therapy, initially with anti-TNF, followed by anti-integrins and anti-interleukins. Despite the different mechanisms of action, there are similarities between the general rates of effectiveness. These similar results were also evidenced in JAK inhibitors and S1p modulators, the last therapeutic classes approved for the treatment of IBD. |
format | Online Article Text |
id | pubmed-10537095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105370952023-09-29 Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years Imbrizi, Marcello Magro, Fernando Coy, Claudio Saddy Rodrigues Pharmaceuticals (Basel) Review Inflammatory Bowel Diseases had their first peak in incidence in countries in North America, Europe, and Oceania and are currently experiencing a new acceleration in incidence, especially in Latin America and Asia. Despite technological advances, 90 years after the development of the first molecule for the treatment of IBD, we still do not have drugs that promote disease remission in a generalized way. We carried out a narrative review on therapeutic advances in the treatment of IBD, the mechanisms of action, and the challenges facing the therapeutic goals in the treatment of IBD. Salicylates are still used in the treatment of Ulcerative Colitis. Corticosteroids have an indication restricted to the period of therapeutic induction due to frequent adverse events, while technologies with less systemic action have been developed. Most immunomodulators showed a late onset of action, requiring a differentiated initial strategy to control the disease. New therapeutic perspectives emerged with biological therapy, initially with anti-TNF, followed by anti-integrins and anti-interleukins. Despite the different mechanisms of action, there are similarities between the general rates of effectiveness. These similar results were also evidenced in JAK inhibitors and S1p modulators, the last therapeutic classes approved for the treatment of IBD. MDPI 2023-09-08 /pmc/articles/PMC10537095/ /pubmed/37765080 http://dx.doi.org/10.3390/ph16091272 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Imbrizi, Marcello Magro, Fernando Coy, Claudio Saddy Rodrigues Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years |
title | Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years |
title_full | Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years |
title_fullStr | Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years |
title_full_unstemmed | Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years |
title_short | Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years |
title_sort | pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537095/ https://www.ncbi.nlm.nih.gov/pubmed/37765080 http://dx.doi.org/10.3390/ph16091272 |
work_keys_str_mv | AT imbrizimarcello pharmacologicaltherapyininflammatoryboweldiseasesanarrativereviewofthepast90years AT magrofernando pharmacologicaltherapyininflammatoryboweldiseasesanarrativereviewofthepast90years AT coyclaudiosaddyrodrigues pharmacologicaltherapyininflammatoryboweldiseasesanarrativereviewofthepast90years |